Wall Street analysts forecast PINC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PINC is 26.80 USD with a low forecast of 21.00 USD and a high forecast of 28.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast PINC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PINC is 26.80 USD with a low forecast of 21.00 USD and a high forecast of 28.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
5 Hold
1 Sell
Hold
Current: 28.260
Low
21.00
Averages
26.80
High
28.25
Current: 28.260
Low
21.00
Averages
26.80
High
28.25
Piper Sandler
Jessica Tassan
Neutral
maintain
$28
2025-11-05
Reason
Piper Sandler
Jessica Tassan
Price Target
$28
2025-11-05
maintain
Neutral
Reason
Piper Sandler analyst Jessica Tassan raised the firm's price target on Premier to $28.25 from $28 and keeps a Neutral rating on the shares. The firm cites quarterly results and the upcoming shareholder vote on the sale of the company to Patient Square Capital.
UBS
Kevin Caliendo
Neutral
maintain
$26
2025-09-25
Reason
UBS
Kevin Caliendo
Price Target
$26
2025-09-25
maintain
Neutral
Reason
UBS analyst Kevin Caliendo raised the firm's price target on Premier to $28.25 from $26 and keeps a Neutral rating on the shares after the company entered into an agreement to be acquired by an affiliate of Patient Square Capital for $28.25 per share in cash.
Canaccord
Richard Close
Hold
maintain
$25
2025-09-23
Reason
Canaccord
Richard Close
Price Target
$25
2025-09-23
maintain
Hold
Reason
Canaccord analyst Richard Close raised the firm's price target on Premier to $28.25 from $25 and keeps a Hold rating on the shares. The firm noted it was announced that Premier entered into a definitive agreement to be acquired by an affiliate of Patient Square Capital for $28.25 per share or a transaction value of roughly $2.6 billion. The deal has been unanimously approved by Premier's Board of Directors and Canaccord sees the transaction as favorable to shareholders as the stock lacks near-term catalysts.
Piper Sandler
Jessica Tassan
Neutral
maintain
$24 -> $28
2025-08-25
Reason
Piper Sandler
Jessica Tassan
Price Target
$24 -> $28
2025-08-25
maintain
Neutral
Reason
Piper Sandler analyst Jessica Tassan raised the firm's price target on Premier to $28 from $24 and keeps a Neutral rating on the shares. The firm notes Premier is executing on renewals in SCS and on Advisory/ Consulting in performance services. Back half weighted FY26 guide, however, coincides with significant industry risk at the start of 2026 and keeps Piper on the sidelines.
About PINC
Premier, Inc. is a technology-driven healthcare improvement company, providing solutions to all healthcare providers in the United States. It offers data and analytics, collaboratives, supply chain solutions, consulting and other services. It unites providers, suppliers, payers and policymakers to create a connected, efficient and patient-focused healthcare system. It conducts all its business operations through Premier Healthcare Solutions, Inc. (PHSI) and its other subsidiaries. Its segments include Supply Chain Services and Performance Services. The Supply Chain Services segment includes its group purchasing organization (GPO), supply chain co-management, purchased services activities, and the digital invoicing and payables automation business. The Performance Services segment consists of its technology and services platform and direct-to-employer business. Its EMR-agnostic platform marries clinical and financial data at the point of care to help providers make clinical decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
